Effect of Angiotensin Receptor blockers on Insulin Resistance in End Stage Renal Disease Patients with Maintenance Hemodialysis
Phase 4
Completed
- Conditions
- end stage renal diseaseinsulin resistanceinsulin hypersensitivitykidney diseaseangiotensin receptor blocker
- Registration Number
- TCTR20130901001
- Lead Sponsor
- Phramongkutklao hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Age> 18 year
Chronic hemodialysis at least 3 months
Adequate dialysis with spKt/V>1.2 and 3 time per weeks
No insulin treatment
Exclusion Criteria
all malignancy
active infection
congestive heart failure FC III-IV
recent cardiovascular disease or cerebrovascular disease with 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link ARBs to improved insulin resistance in ESRD patients on hemodialysis?
How do ARBs compare to standard-of-care therapies for managing insulin resistance in hemodialysis-treated ESRD patients?
Which biomarkers correlate with ARB efficacy in ESRD patients with insulin resistance and maintenance hemodialysis?
What adverse events are associated with ARB use in ESRD patients during hemodialysis and their management strategies?
Are there combination therapies involving ARBs that enhance insulin sensitivity in ESRD patients with hemodialysis?